

Increased Phospho-AKT in Blood Cells from *LRRK2* G2019S Mutation Carriers

Alicia Garrido, MD ^{1,2,3†},
 Leticia Pérez-Sisqués, PhD ^{4,5†},
 Cristina Simonet, MD, ^{1,2,3}
 Genís Campoy-Campos, MSc, ^{4,5}
 Júlia Solana-Balaguer, MSc, ^{4,5}
 Núria Martín-Flores, PhD, ^{4,5}
 Manel Fernández, MSc, ^{1,2,5}
 Marta Soto, MSc, ^{1,2,3}
 Donina Obiang, RN, ^{1,2,3}
 Ana Cámara, RN, ^{1,2,3}
 Francesc Valldeoriola, MD, PhD, ^{1,2,3}
 Esteban Muñoz, MD, PhD, ^{1,2,3}
 Yaroslau Compta, MD, PhD, ^{1,2,3}
 Esther Pérez-Navarro, PhD, ^{3,4,5}
 Jordi Alberch, PhD, ^{3,4,5}
 Eduardo Tolosa, MD, PhD ^{1,2,3}
 María-José Martí, MD, PhD, ^{1,2,3}
 Mario Ezquerra, PhD ^{1,2,3‡}
 Cristina Malagelada, PhD ^{3,4,5‡} and
 Rubén Fernández-Santiago, PhD ^{1,2,3,4‡}

The purpose of this study was to investigate whether differential phosphorylation states of blood markers can identify patients with *LRRK2* Parkinson's disease (PD). We assessed phospho(P)-Ser-935-*LRRK2* and P-Ser-473-AKT levels in peripheral blood cells from patients with G2019S *LRRK2*-associated PD (L2PD, $n = 31$), G2019S *LRRK2* non-manifesting carriers (L2NMC, $n = 26$), idiopathic PD (iPD, $n = 25$), and controls ($n = 40$, total $n = 122$). We found no differences at P-Ser-935-*LRRK2* between groups but detected a specific increase of P-Ser-473-AKT levels in all G2019S carriers, either L2PD or L2NMC, absent in iPD. Although insensitive to *LRRK2* inhibition, our study identifies P-Ser-473-AKT as an endogenous candidate biomarker for peripheral inflammation in G2019S carriers using accessible blood cells.

ANN NEUROL 2022;92:888–894

Lucine-rich repeat kinase 2 (*LRRK2*) mutations cause *LRRK2*-associated Parkinson's disease (L2PD), the most frequent form of monogenic Parkinson's disease (PD), which

has a clinicopathological phenotype similar to idiopathic PD (iPD).¹ Non-manifesting *LRRK2* mutation carriers (L2NMCs) are at high risk of PD but predicting disease onset is challenging given the low penetrance and the lack of progression biomarkers.^{2,3} In vitro, *LRRK2* pathogenic mutations, including G2019S at the Serine (Ser) / Threonine (Thr) kinase, or R1441G at the GTPase ROC domains, increase *LRRK2* kinase activity in neurons by a toxic gain-of-function.⁴ Thus, the P-Ser-1292-*LRRK2* and P-Ser-935-*LRRK2* phospho-sites reflecting auto-phosphorylation or phosphorylation by upstream kinases, respectively,⁵ represent candidate biomarkers for target engagement in *LRRK2* inhibitor clinical trials.⁶ Decreased blood P-Ser-935-*LRRK2* levels have been described in patients' with L2PD compared to L2NMC only but not to controls in North Americans,⁷ but not validated in another study using the same cohort.⁸ Increased P-Thr-73-RAB10 levels, the only known endogenous substrate of *LRRK2*,⁹ has been shown in a large cohort of patients with L2PD carrying the R1441G mutation, but not for G2019S.¹⁰ Therefore, biomarker research in L2PD needs to be evaluated and expanded in additional cohorts.

From the ¹Parkinson Disease and Movement Disorders Unit, Neurology Service, Institut Clínic de Neurociències, Hospital Clínic de Barcelona, Barcelona, Spain; ²Laboratory of Parkinson Disease and Other Neurodegenerative Movement Disorders, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Institut de Neurociències, Universitat de Barcelona, Barcelona, Spain; ³Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED: CB06/05/0018-ISCIII), Barcelona, Spain; ⁴Department of Biomedicine, Faculty of Medicine, Universitat de Barcelona, Barcelona, Spain; and ⁵Institut de Neurociències, Universitat de Barcelona, Barcelona, Spain

Address correspondence to Dr Fernández-Santiago and Mario Ezquerra, Laboratory of Parkinson Disease and Other Neurodegenerative Movement Disorders, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Institut de Neurociències, Universitat de Barcelona, IDIBAPS-Hospital Clínic de Barcelona, CELLEX Building, Casanova 143, Floor 3B, 08036 Barcelona, Catalonia, Spain. E-mail: ruben.fernandez.santiago@gmail.com; ezquerra@clinic.cat and Dr Cristina Malagelada, Unit of Biochemistry and Molecular Biology, Department of Biomedicine, Faculty of Medicine, Universitat de Barcelona, Casanova 143, 08036 Barcelona, Catalonia, Spain. E-mail: cristina.malagelada@ub.edu

Additional supporting information can be found in the online version of this article.

Received Mar 28, 2022, and in revised form Jul 15, 2022. Accepted for publication Jul 29, 2022.

View this article online at wileyonlinelibrary.com. DOI: 10.1002/ana.26469.

[†]Alicia Garrido MD, and Leticia Pérez-Sisqués PhD these authors have contributed equally to this work.

[‡]Mario Ezquerra PhD, Cristina Malagelada PhD and Rubén Fernández Santiago PhD these authors should be considered joint senior authors.

The AKT Ser/Thr kinase 1 (AKT) is a central hub in the key PI3K/AKT/mTOR pathway. AKT is ubiquitously expressed and has a critical role in regulating diverse cellular signals, managing the balance between catabolism and anabolism.¹¹ Moreover, AKT is related to broad physiological functions across cells, tissues, and pathologies, including cancer, autoimmune diseases, and neurodegenerative disorders.¹¹ P-Ser-473-AKT has been proposed as an *LRRK2* phosphorylation substrate in PD animal models¹² and L2PD induced pluripotent stem cell (iPSC)-derived neurons.¹³ In addition, postmortem iPD nigral neurons had diminished P-Ser-473-AKT levels,^{14,15} whereas fibroblasts from patients with L2PD showed increased AKT signaling.¹⁶ Overall, it is expected that phospho-protein differences related to common *LRRK2* mutations, such as G2019S, could act as progression or drug response biomarkers for L2NMC and L2PD. Here, we expanded biomarker research in G2019S mutation carriers from PD by analyzing the endogenous levels of P-Ser-935-LRRK2, P-Ser-1292-LRRK2, and P-Ser-473-AKT in peripheral blood mononuclear cells (PBMCs) from a large Spanish *LRRK2* cohort (n = 111) encompassing patients with G2019S L2PD, PD at-risk G2019S L2NMC, patients with iPD, and controls. To further assess the potential direct effects of G2019S on P-Ser-935-LRRK2 and P-Ser-473-AKT, we collected fresh PBMC lysates from additional subjects (n = 11), including patients with heterozygous and homozygous G2019S L2PD, heterozygous R1441G L2PD, and controls. We treated these samples with the 3-(4-Pyrimidinyl) Indazole (MLi-2),¹⁷ a potent and selective *LRRK2* inhibitor that reduces its kinase activity.

Methods

Subjects

Blood samples were obtained at the Movement Disorders Unit from the Hospital Clínic de Barcelona as part of the Barcelona *LRRK2* biorepository cohort supported by the Michael J. Fox

Foundation for Parkinson's research (MJFF) at our center. The ethics committee of the Hospital Clínic de Barcelona approved the study, and all subjects gave written informed consent. PD diagnosis was made according to the UK PD Society Brain Bank criteria, except that more than one affected relative with PD was not an exclusion criterion.¹⁸ The studied cohort included 111 subjects consisting of heterozygous G2019S L2PD (n = 25) and G2019S L2NMC (n = 25), patients with iPD (n = 25), and healthy controls (n = 36; Table). The patients with iPD and controls were age-matched with patients with L2PD, and the L2NMC were recruited as available. We selected the healthy control group from among the spouses from the patients with PD visiting our outpatient clinic and other genetically unrelated relatives, caregivers, or friends. To further assess the effects of the MLI-2 *LRRK2* kinase inhibitor on P-Ser-935-LRRK2, P-Ser-1292-LRRK2, and P-Ser-473-AKT, we additionally collected fresh PBMC samples from 11 subjects, including heterozygous G2019S L2PD (n = 5), homozygous G2019S L2PD (n = 1), heterozygous R1441G L2PD (n = 1), and healthy controls (n = 4; Table S1). Except for one homozygous G2019S carrier with North-Arab Berber origin, all participants were White race of Spanish descent.

Genotyping

We used commercial Taqman SNP assays on-demand on a Step One Plus Real-time PCR System (Life Tech) to genotype the *LRRK2* G2019S mutation (Thermo Fisher Scientific; #C-63498123-10) and R1441G/C/H, as previously described.¹⁹ The studied *LRRK2* mutations were absent in the patients with iPD and healthy controls. No systematic sequencing was done to exclude additional mutations causing monogenic PD in iPD cases.

PBMC Isolation

A total of 8ml of blood was drawn by peripheral vein puncture in fasting. PBMCs were isolated by density gradient using sodium-citrate collector tubes according to

TABLE: Clinicodemographic Features from Patients With G2019S L2PD, L2NMC, iPD, and Healthy Controls

| Subjects (n = 111) | Mean age (yr) ± SD | Sex (male %) | Disease duration | Mean MDS UPDRS-III ± SD | Mean H&Y ± SD | Mean S&E (minimum - maximum) |
|--------------------|--------------------|--------------|------------------|-------------------------|---------------|------------------------------|
| L2PD (n = 25) | 65.28 ± 11.16 | 32% | 10.84 ± 9.92 | 24.08 ± 12.83 | 1.96 ± 0.78 | 89% (70–100) |
| L2NMC (n = 25) | 51.13 ± 13.34 | 48% | 0 | 1.96 ± 2.72 | 0 | 100% |
| iPD (n = 25) | 69.12 ± 9.88 | 60% | 7.64 ± 7.23 | 21.32 ± 11.10 | 1.72 ± 0.54 | 96% (70–100) |
| C (n = 36) | 66.33 ± 11.54 | 55% | 0 | 3.56 ± 3.30 | 0 | 100% |

Abbreviations: C = healthy controls; H&Y = Hoehn and Yahr motor disability scoring; iPD = idiopathic Parkinson's disease; L2NMC = non-manifesting *LRRK2* G2019S carriers; L2PD = *LRRK2*-associated Parkinson's disease; MDS UPDRS III, Unified Parkinson's Disease Rating Scale scoring from the Movement Disorders Society; S&E = Schwab and England activities of daily living scoring; SD, standard deviation.

the manufacturer's instructions (BD Vacutainer CPT, #EAN30382903627821). Dry pellets were flash-frozen in liquid N₂ and stored at -80°C until use.

Supplementary Methods

Please see Supplementary Methods for Western blotting analysis and LRRK2 inhibition by MLI-2 treatment.

Results

Analysis by Western blot of PBMCs from patients with G2019S L2PD, G2019S L2NMC, iPD, and controls

showed similar levels of total LRRK2 and P-Ser-935-LRRK2 across groups (Fig 1B, C). On the contrary, we observed statistically significant phospho-protein differences for P-Ser-473-AKT (Kruskal-Wallis test; $p = 0.0031$). More specifically, all G2019S mutation carriers as a group (ie, L2PD and L2NMC), showed increased P-Ser-473-AKT levels compared to controls (Fig 1E; Dunn test adjusted $p = 0.0022$) or iPD (see Fig 1E; Dunn test adjusted $p = 0.0260$). Segregating by disease status, we also found increased P-Ser-473-AKT in G2019S L2PD (Fig 1D; Dunn test adjusted $p = 0.0353$) and G2019S L2NMC independently compared to controls (Fig 1D; Dunn test adjusted $p = 0.0170$), but no changes in




FIGURE 1: Analysis of LRRK2 and AKT phosphorylation levels in PBMC lysates from G2019S L2PD, G2019S L2NMC, iPD, and healthy controls. (A) Western blotting analysis of representative samples (MW = molecular weight in kDa). (B) Total LRRK2 protein levels relative to total Akt. (C) P-Ser-935-LRRK2 levels relative to total LRRK2. (D) P-Ser-473-AKT levels relative to total Akt. (E) P-Ser-273-AKT levels in all G2019S mutation carriers (L2PD and L2NMC). Bar plot data is represented as mean \pm standard error of the mean (SEM; samples included in the densitometry analyses in A: 21 L2PD, 22 L2NMC, 24 iPD, and 32 C; B: 24 L2PD, 23 L2NMC, 23 iPD, and 31 C; C: 23 L2PD, 24 L2NMC, 22 iPD, and 30 C; D: 47 G2019S carriers, 22 iPD, and 30 C). Group comparisons were made using Kruskal-Wallis analysis followed by Dunn post hoc test. Statistical significance is referred as (*) p below 0.05; (**) p below 0.01. iPD = idiopathic Parkinson's disease; L2NMC = non-manifesting LRRK2 G2019S carriers; L2PD = LRRK2-associated Parkinson's disease; PBMC = peripheral blood mononuclear cell.




FIGURE 2: Analysis of AKT phosphorylation in PBMC lysates from (A) healthy donors and (B) patients with L2PD treated with small-molecule LRRK2 inhibitors. LRRK2 kinase activity was inhibited with 1 hour treatment of 100 nM 3-(4-Pyrimidinyl) Indazole (MLI-2) using DMSO as a vehicle. Inhibition of LRRK2 is proved by the decrease in RAB10 and LRRK2 phosphorylation levels (P-Thr-73-RAB10 and P-Ser-935-LRRK2). (A) (i) Western blotting panels of PBMCs protein extracts from healthy donors D1 to D4 ($n = 4$). (ii) Densitometric analysis of P-Ser-473-AKT protein levels relative to total AKT, P-Thr-73-RAB10 relative to total RAB10, and P-Ser-935-LRRK2 relative to total LRRK2. (B) (i) Western blotting panels of PBMCs from study subjects S1 to S7 ($n = 7$), including patients with L2PD carrying the mutations G2019S or R1441G in heterozygosis (het.) or homozygosis (hom.). Densitometric analysis of P-Ser-473-AKT levels relative to total AKT, P-Thr-73-RAB10 relative to total RAB10 and P-Ser-935-LRRK2 relative to total LRRK2 in (ii) L2PD G2019S heterozygous patients ($n = 5$), (iii) a patient with L2PD G2019S homozygous ($n = 1$) and (iv) a patient with L2PD R1441G homozygous ($n = 1$). In every patient, the densitometric value is normalized to its respective DMSO control as percentage of change after MLI-2 treatment. Data were analyzed by Student's t test ($p < 0.001$ vs. DMSO control). L2PD = LRRK2-associated Parkinson's disease; PBMC = peripheral blood mononuclear cell.**

iPD. These results indicate that increased P-Ser-473-AKT levels are associated with the G2019S mutation suggesting augmented P-Ser-473-AKT phosphorylation as a state marker of G2019S carriers, either patients with L2PD or patients with PD with at-risk L2NMC.

To further investigate whether P-Ser-473-AKT upregulation may be related to enhanced kinase activity of G2019S mutant LRRK2, we subsequently collected fresh PBMC samples from 11 additional subjects, including 5 patients with heterozygous G2019S L2PD, one patient with homozygous G2019S L2PD, one patient with heterozygous R1441G L2PD, and 4 healthy controls (Fig 2). In parallel, we treated these PBMC samples either with the LRRK2 kinase inhibitor MLI-2 (100 nM, 1 hour) or the DMSO vehicle alone. Whereas the MLI-2 treatment significantly reduced P-Ser-935-LRRK2 and P-Thr-73-RAB10 levels in G2019S carriers and controls, we observed no significant effect of MLI-2 on P-Ser-473-AKT levels. Interestingly, patients with G2019S L2PD under LRRK2 inhibition showed a trend toward lower levels of P-Ser-473-AKT, which warrants further investigation.

Discussion

Ours is the first study reporting increased P-Ser-473-AKT levels in blood cells from G2019S carriers, either patients with L2PD with a manifest disease or L2NMC at risk of PD, but not in iPD indicating an association with the G2019S mutation. Different groups have reported that in the central nervous system, AKT activation by phosphorylation at Ser-473 promotes neuroprotection in PD and other neurodegenerative disorders, such as Alzheimer's disease (AD)^{14,20,21} or Huntington's disease.^{22,23} In neural tissue from *Drosophila* PD models, P-Ser-473-AKT was proposed as a downstream target of LRRK2, although these findings have not been further replicated yet.¹² In addition, human *LRRK2* G2019S and R1441C dopaminergic neurons showed enhanced apoptosis mediated by decreased P-Ser-473-AKT levels.²⁴ Moreover, neurodegeneration mediated by low P-Ser-473-AKT was described in iPSC-derived neurons of patients with PD carrying the *LRRK2* I2020T pathogenic mutation from the Japanese family from Sagami-hara, in which the *LRRK2* locus PARK8 was first reported.¹²

However, in peripheral non-neural tissues from various disease models, P-Ser-473-AKT activation has been linked to inflammation, indicating different tissue-specific effects of AKT deregulation (eg, promoting neutrophil²⁵ and lymphocyte survival),²⁶ or platelet activation.²⁷ Similarly, autoimmune disorders with inflammation, such as systemic lupus erythematosus, exhibited increased P-Ser-473-AKT.^{28–30} In neurological diseases with a recognized immune component, such as AD, enhanced AKT signaling led to neuroinflammation

by activating microglia, consistent with its peripheral immune origin.^{31,32} In PD, α -synuclein fibrils treatment of microglia showed increased AKT phosphorylation.³⁰ Another study in G2019S fibroblasts from patients with L2PD reported peripheral AKT activation at Thr-308.¹⁶ Indeed, *LRRK2* mutations have been associated with inflammatory disease in G2019S L2PD and L2NMC.^{29,33–35} Our findings of high P-Ser-473-AKT levels in blood cells from G2019S carriers support the recently recognized immune component of PD at multiple levels,^{36–39} and may hold potential therapeutic implications for peripheral modulation of AKT.

We also observed that elevated P-Ser-473-AKT levels were insensitive to LRRK2 inhibition by MLI-2,¹⁷ suggesting that AKT is not a direct substrate of LRRK2, at least in blood cells. Nevertheless, crosstalk between LRRK2 and other kinases with a preference for P-Ser-473-AKT cannot be ruled out. Moreover, increased P-Ser-473-AKT levels directly related to enhanced LRRK2 activity (ie, reversible by MLI-2),¹⁷ were shown in peripheral phagocytes only in the physiological context of active macropinocytosis,⁴⁰ suggesting potentially different effects in vivo and in cell pellets. In our study, the differential P-Ser-473-AKT levels in G2019S carriers identify phospho-AKT as a candidate biomarker of chronic inflammation associated with the G2019S mutation^{33,34} in L2PD and L2NMC. P-Ser-473-AKT could serve as a pharmacodynamic readout of AKT modulation in L2PD clinical trials of AKT inhibitors reducing inflammation in blood cells or microglia. This point is relevant given that several AKT modulation strategies are being explored in neurodegenerative diseases, including AD or PD.^{41,42} If valid, similarly as proposed for LRRK2 inhibitors,^{3,43} initiation of AKT modulators in L2NMC would be an option to investigate in future clinical trials.

Our study also found that P-Ser-935-LRRK2 levels were similar in PBMCs from patients with G2019S L2PD, G2019S L2NMC, iPD, and controls. P-Ser-935-LRRK2 phosphorylation is catalyzed by other kinases upstream of LRRK2.⁵ Results in previous studies have been slightly contradictory, with one study showing decreased P-Ser-935-LRRK2 in G2019S L2PD PBMCs compared to iPD only but not with controls,⁷ and another study using PBMCs from the same LRRK2 cohort⁷ reporting no P-Ser-935-LRRK2 changes in G2019S L2PD or G2019S L2NMC versus controls but increased levels in iPD.⁸ Although these studies^{7,8} used sensitive enzyme-linked immunosorbent assay (ELISA)-based methods with broader detection dynamic ranges than Western blotting, the sample size and antibodies were similar to our study (Table S2). In addition, one Western blotting analysis of LRRK2 neutrophils showed no P-Ser-935-LRRK2 differences in G2019S L2PD or iPD versus controls.¹⁰ Altogether, these works agree in reporting no P-Ser-935-LRRK2 differences between G2019S

carriers and controls, indicating that P-Ser-935-LRRK2 is not an endogenous biomarker of G2019S carriers. Yet, P-Ser-935-LRRK2 represents an appealing pharmacodynamic readout for LRRK2 target engagement,^{44,45} as we also observed by treating fresh PBMCs with MLi-2.

There are 2 unmet needs in the LRRK2 field. First, it is unknown why some LRRK2 carriers develop PD and some do not, which our study does not resolve, given that P-Ser-473-AKT levels were equally increased in all G2019S carriers regardless of their disease status. Second, there is a limited target engagement in L2PD clinical trials, especially for early neuroprotective measures before the motor onset. Our study explicitly tackles the former need by identifying P-Ser-473-AKT as a novel candidate biomarker of peripheral inflammation in G2019S carriers. However, future phospho-AKT studies in longitudinal LRRK2 cohorts are needed. In summary, we have identified P-Ser-473-AKT as an endogenous candidate biomarker of peripheral inflammation in LRRK2 G2019S carriers using accessible blood cells. Our findings warrant further assessment in additional G2019S cohorts and, if validated, may hold implications for clinical trials investigating AKT modulators in L2PD but also in other neurological diseases cursing with peripheral inflammation.

Acknowledgments

The authors thank all the patients and their relatives for their continued collaboration. We also thank Dr. Esther Sammler (University of Dundee, Scotland, UK) for her valuable collaboration in sharing data and protocols, and Dr. Lorena de Mena (IDIBAPS-Hospital Clínic of Barcelona, Spain) for critical revision and input to the manuscript.

This work was funded by the Michael J. Fox Foundation for Parkinson's Research (MJFF; grant #11849) to M.J.-M. and E.T., and (grant #MJFF-000858) to R.F.-S., M. E., and C.M. G.C. was funded by a FI-2021 grant from the Agència de Gestió d'Ajuts Universitaris de Recerca (AGAUR; grant #FI-B-00378). J.S. was funded by a FPU grant from the Spanish Ministry of Science, Innovation and Universities (MICIU; grant #FPU18/00194). M.F. was funded through a María de Maeztu grant (grant #MDM-2017-0729) to the Parkinson Disease and Movement Disorders Group of the Institut de Neurociències (Universitat de Barcelona). E.P. was funded by the Spanish Ministry of Economy and Competitiveness (MINECO; AEI/FEDER/EU; grant #PID2019-106447RB-I00). J.A. was funded by the Spanish Ministry of Economy and Competitiveness (MINECO; AEI/FEDER/EU; grants #SAF2017-88076 and #PID2020-119386R-I00). C.M. was funded by the Spanish Ministry of Economy and Competitiveness (MINECO; AEI/FEDER/EU; grants #SAF2017-88812-R and

PID2020-119236RB-I00). R.F.-S. was supported by a Miguel Servet grant (grant #CP19/00048) and an FIS grant (grant #CP19/00048) from the Instituto de Salud Carlos III (ISCIII) co-funded by the European Union, and a Jóvenes Investigadores (JIN) grant of the Spanish Ministry of Economy and Competitiveness (MINECO) and the Agencia Estatal de Investigación (AEI; AEI/FEDER/EU; grant #SAF2015-73508-JIN). IDIBAPS receives support from the CERCA programme of Generalitat de Catalunya.

Author Contributions

R.F.-S., C.M., M.E., and M.J.M. contributed to conception and design of the study. All authors contributed to the acquisition and analysis of data. R.F.-S., M.E., C.M., A.G., L.P.-S., G.C.-C., J.S.-B., and N.M.-F. contributed to drafting the text or preparing the figures.

Potential Conflicts of Interest

The authors declared no conflict of interest.

References

- Gaig C, Martí MJ, Ezquerro M, et al. G2019S LRRK2 mutation causing Parkinson's disease without Lewy bodies. *J Neurol Neurosurg Psychiatry* 2007;78:626–628. <https://doi.org/10.1136/jnnp.2006.107904>.
- Hentati F, Trinh J, Thompson C, et al. LRRK2 parkinsonism in Tunisia and Norway: a comparative analysis of disease penetrance. *Neurology* 2014; 83:568–569. <https://doi.org/10.1212/WNL.0000000000000675>.
- Tolosa E, Vila M, Klein C, Rascol O. LRRK2 in Parkinson disease: challenges of clinical trials. *Nat Rev Neurol* 2020;16:97–107. <https://doi.org/10.1038/s41582-019-0301-2>.
- West AB, Moore DJ, Biskup S, et al. Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. *Proc Natl Acad Sci U S A* 2005;102:16842–16847. <https://doi.org/10.1073/pnas.0507360102>.
- Marchand A, Drouyer M, Sarchione A, et al. LRRK2 phosphorylation, more than an epiphenomenon. *Front Neurosci* 2020;14:527. <https://doi.org/10.3389/fnins.2020.00527>.
- Fan Y, Howden AJM, Sarhan AR, et al. Interrogating Parkinson's disease LRRK2 kinase pathway activity by assessing Rab10 phosphorylation in human neutrophils. *Biochem J* 2018;475:23–44. <https://doi.org/10.1042/BCJ20170803>.
- Padmanabhan S, Lanz TA, Gorman D, et al. An assessment of LRRK2 serine 935 phosphorylation in human peripheral blood mononuclear cells in idiopathic Parkinson's disease and G2019S LRRK2 cohorts. *J Parkinsons Dis* 2020;10:623–629. <https://doi.org/10.3233/JPD-191786>.
- Melachroinou K, Kang MS, Liong C, et al. Elevated in vitro kinase activity in peripheral blood mononuclear cells of leucine-rich repeat kinase 2 G2019S carriers: a novel enzyme-linked immunosorbent assay-based method. *Mov Disord* 2020; 35(11):2095–2100. <https://doi.org/10.1002/mds.28175>.
- Seol W, Nam D, Son I. Rab GTPases as physiological substrates of LRRK2 kinase. *Exp Neurobiol* 2019;28:134–145. <https://doi.org/10.5607/en.2019.28.2.134>.
- Fan Y, Nirujogi RS, Garrido A, et al. R1441G but not G2019S mutation enhances LRRK2 mediated Rab10 phosphorylation in human peripheral blood neutrophils. *Acta Neuropathol* 2021;142:475–494. <https://doi.org/10.1007/s00401-021-02325-z>.

11. Manning BD, Toker A. AKT/PKB signaling: navigating the network. *Cell* 2017;169:381–405. <https://doi.org/10.1016/J.CELL.2017.04.001>.
12. Chuang CL, Lu YN, Wang HC, Chang HY. Genetic dissection reveals that Akt is the critical kinase downstream of LRRK2 to phosphorylate and inhibit FOXO1, and promotes neuron survival. *Hum Mol Genet* 2014;23:5649–5658. <https://doi.org/10.1093/hmg/ddu281>.
13. Ohta E, Nihira T, Uchino A, et al. I2020T mutant LRRK2 iPSC-derived neurons in the Sagami-hara family exhibit increased tau phosphorylation through the AKT/GSK-3 β signaling pathway. *Hum Mol Genet* 2015;24:4879–4900. <https://doi.org/10.1093/hmg/ddv212>.
14. Malagelada C, Zong HJ, Greene LA. RTP801 is induced in Parkinson's disease and mediates neuron death by inhibiting Akt phosphorylation/activation. *J Neurosci* 2008;28:14363–14371. <https://doi.org/10.1523/JNEUROSCI.3928-08.2008>.
15. Torres AS, Holz MK. Unraveling the multifaceted nature of the nuclear function of mTOR. *Biochim Biophys Acta Mol Cell Res* 2021;1868:118907. <https://doi.org/10.1016/J.BBAMCR.2020.118907>.
16. Funk N, Munz M, Ott T, et al. The Parkinson's disease-linked leucine-rich repeat kinase 2 (LRRK2) is required for insulin-stimulated translocation of GLUT4. *Sci Rep* 2019;9:4515. <https://doi.org/10.1038/s41598-019-40808-y>.
17. Scott JD, DeMong DE, Greshock TJ, et al. Discovery of a 3-(4-Pyrimidinyl) Indazole (MLi-2), an orally available and selective leucine-rich repeat kinase 2 (LRRK2) inhibitor that reduces brain kinase activity. *J Med Chem* 2017;60:2983–2992. <https://doi.org/10.1021/ACS.JMEDCHEM.7B00045>.
18. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. *J Neurol Neurosurg Psychiatry* 1992;55:181–184.
19. Simon-Sanchez J, Marti-Masso JF, Sanchez-Mut JV, et al. Parkinson's disease due to the R1441G mutation in Dardarin: a founder effect in the Basques. *Mov Disord* 2006;21:1954–1959. <https://doi.org/10.1002/mds.21114>.
20. Rai SN, Dilnashin H, Birla H, et al. The role of PI3K/Akt and ERK in neurodegenerative disorders. *Neurotox Res* 2019;35:775–795. <https://doi.org/10.1007/S12640-019-0003-Y>.
21. Timmons S, Coakley MF, Moloney AM, O' Neill C. Akt signal transduction dysfunction in Parkinson's disease. *Neurosci Lett* 2009;467:30–35. <https://doi.org/10.1016/j.neulet.2009.09.055>.
22. Saavedra A, García-Martínez JM, Xifró X, et al. PH domain leucine-rich repeat protein phosphatase 1 contributes to maintain the activation of the PI3K/Akt pro-survival pathway in Huntington's disease striatum. *Cell Death Differ* 2010;17:324–335. <https://doi.org/10.1038/CDD.2009.127>.
23. Creus-Muncunill J, Rué L, Alcalá-Vida R, et al. Increased levels of Rictor prevent mutant huntingtin-induced neuronal degeneration. *Mol Neurobiol* 2018;55:7728–7742. <https://doi.org/10.1007/S12035-018-0956-5>.
24. Lin CH, Lin HI, Chen ML, et al. Lovastatin protects neurite degeneration in LRRK2-G2019S parkinsonism through activating the Akt/Nrf pathway and inhibiting GSK3 β activity. *Hum Mol Genet* 2016;25:1965–1978. <https://doi.org/10.1093/hmg/ddw068>.
25. Sousa LP, Lopes F, Silva DM, et al. PDE4 inhibition drives resolution of neutrophilic inflammation by inducing apoptosis in a PKA-PI3K/Akt-dependent and NF- κ B-independent manner. *J Leukoc Biol* 2010;87:895–904. <https://doi.org/10.1189/jlb.0809540>.
26. Bommhardt U, Chang KC, Swanson PE, et al. Akt decreases lymphocyte apoptosis and improves survival in sepsis. *J Immunol* 2004;172:7583–7591. <https://doi.org/10.4049/jimmunol.172.12.7583>.
27. Borst O, Münzer P, Gatidis S, et al. The inflammatory chemokine CXC motif ligand 16 triggers platelet activation and adhesion via CXC motif receptor 6-dependent phosphatidylinositolide 3-kinase/akt signaling. *Circ Res* 2012;111:1297–1307. <https://doi.org/10.1161/CIRCRESAHA.112.276444>.
28. Tang H, Tan G, Guo Q, et al. Abnormal activation of the Akt-GSK3 β signaling pathway in peripheral blood T cells from patients with systemic lupus erythematosus. *Cell Cycle* 2009;8:2789–2793. <https://doi.org/10.4161/cc.8.17.9446>.
29. Zhang M, Yao C, Cai J, et al. LRRK2 is involved in the pathogenesis of system lupus erythematosus through promoting pathogenic antibody production. *J Transl Med* 2019;17:37. <https://doi.org/10.1186/s12967-019-1786-6>.
30. Han Y, Zeng F, Tan G, et al. Hydrogen sulfide inhibits abnormal proliferation of lymphocytes via AKT/GSK3 β signal pathway in systemic lupus erythematosus patients. *Cell Physiol Biochem* 2013;31:795–804. <https://doi.org/10.1159/000350097>.
31. Lu J, Wang C, Cheng X, et al. A breakdown in microglial metabolic reprogramming causes internalization dysfunction of α -synuclein in a mouse model of Parkinson's disease. *J Neuroinflammation* 2022;19:113. <https://doi.org/10.1186/S12974-022-02484-0>.
32. Alliot F, Godin I, Pessac B. Microglia derive from progenitors, originating from the yolk sac, and which proliferate in the brain. *Brain Res Dev Brain Res* 1999;117:145–152. [https://doi.org/10.1016/S0165-3806\(99\)00113-3](https://doi.org/10.1016/S0165-3806(99)00113-3).
33. Wallings RL, Tansey MG. LRRK2 regulation of immune-pathways and inflammatory disease. *Biochem Soc Trans* 2019;47:1581–1595. <https://doi.org/10.1042/BST20180463>.
34. Dzakmo N, Rowe DB, Halliday GM. Increased peripheral inflammation in asymptomatic leucine-rich repeat kinase 2 mutation carriers. *Mov Disord* 2016;31:889–897. <https://doi.org/10.1002/mds.26529>.
35. Brockmann K, Apel A, Schulte C, et al. Inflammatory profile in LRRK2-associated prodromal and clinical PD. *J Neuroinflammation* 2016;13:122. <https://doi.org/10.1186/s12974-016-0588-5>.
36. Tansey MG, Wallings RL, Houser MC, et al. Inflammation and immune dysfunction in Parkinson disease. *Nat Rev Immunol* 2022;4:1–17. <https://doi.org/10.1038/s41577-022-00684-6>.
37. Gonzalez-Latapi P, Marras C. Epidemiological evidence for an immune component of Parkinson's disease. *J Parkinsons Dis* 2022;30:1–15. <https://doi.org/10.3233/JPD-223180>.
38. Hamza TH, Zabetian CP, Tenesa A, et al. Common genetic variation in the HLA region is associated with late-onset sporadic Parkinson's disease. *Nat Genet* 2010;42:781–785. <https://doi.org/10.1038/NG.642>.
39. Holmans P, Moskvina V, Jones L, et al. A pathway-based analysis provides additional support for an immune-related genetic susceptibility to Parkinson's disease. *Hum Mol Genet* 2013;22:1039–1049. <https://doi.org/10.1093/HMG/DDS492>.
40. Liu Z, Xu E, Zhao HT, et al. LRRK2 and Rab10 coordinate macrophocytosis to mediate immunological responses in phagocytes. *EMBO J* 2020;39(20):e104862. <https://doi.org/10.15252/embj.2020104862>.
41. Razani E, Pourbagheri-Sigaroodi A, Safaroghli-Azar A, et al. The PI3K/Akt signaling axis in Alzheimer's disease: a valuable target to stimulate or suppress? *Cell Stress Chaperones* 2021;26:871–887. <https://doi.org/10.1007/S12192-021-01231-3>.
42. Guttuso T, Andrzejewski KL, Lichter DG, Andersen JK. Targeting kinases in Parkinson's disease: a mechanism shared by LRRK2, neurotrophins, exenatide, urate, nilotinib and lithium. *J Neurol Sci* 2019;402:121–130. <https://doi.org/10.1016/J.JNS.2019.05.016>.
43. Garrido A, Santamaría E, Fernández-Irigoyen J, et al. Differential Phospho-signatures in blood cells identify LRRK2 G2019S carriers in Parkinson's disease. *Mov Disord* 2022;37:1004–1015. <https://doi.org/10.1002/MDS.28927>.
44. Taymans J-M, Greggio E. LRRK2 kinase inhibition as a therapeutic strategy for Parkinson's disease, where do we stand? *Curr Neuropharmacol* 2016;14:214–225. <https://doi.org/10.2174/1570159x13666151030102847>.
45. Dzakmo N, Deak M, Hentati F, et al. Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser 910/Ser935, disruption of 14-3-3 binding and altered cytoplasmic localization. *Biochem J* 2010;430:405–413. <https://doi.org/10.1042/BJ20100784>.